RCT: Nirsevimab for prevention of RSV in healthy late-preterm and term infants.

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants – New England Journal of Medicine

Commentaries:

Nirsevimab Protects Late-Preterm, Term Infants from RSV-Related Lower RTI, Study Finds – AJMC

Nirsevimab Prophylaxis Wards Off RSV Infections in Healthy Infants— Monoclonal antibody showed 74.5% efficacy against RSV infections requiring medical care – MedPage Today (free registration required)

Related: Randomized trial: Single-dose nirsevimab for prevention of RSV in preterm infants